protease inhibitor


Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Wikipedia.
Related to protease inhibitor: fusion inhibitor, Serine protease inhibitor

protease inhibitor

(prō`tē-ās'), any of a class of drugs that interfere with replication of the AIDSAIDS
or acquired immunodeficiency syndrome,
fatal disease caused by a rapidly mutating retrovirus that attacks the immune system and leaves the victim vulnerable to infections, malignancies, and neurological disorders. It was first recognized as a disease in 1981.
..... Click the link for more information.
 virus (HIVHIV,
human immunodeficiency virus, either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States.
..... Click the link for more information.
), by blocking an enzyme (protease) necessary in the late stages of its reproduction. Clinical trials of the protease inhibitor indinavir have shown it to be especially beneficial in combination with the anti-HIV drugs AZTAZT
or zidovudine
, drug used to treat patients infected with the human immunodeficiency virus (HIV), which causes AIDS; also called azidothymidine. Originally developed in 1964 as an anticancer drug, AZT was never approved for that purpose.
..... Click the link for more information.
 and 3TC, which act by blocking a different enzyme, reverse transcriptase. Saquinavir, the first member of the class to be marketed, was approved for use in 1995 by the Food and Drug Administration.
References in periodicals archive ?
Even when Prezista did fail in this study, virus resistant to protease inhibitors and nucleosides was less likely to develop than when Kaletra failed.
With the introduction of 3 protease inhibitors within a few months of each other, there was tremendous marketing pressure from the 3 companies that manufactured these products, leading to intense debates among the companies involved.
Kelly JA, Hoffman RG, Rompa D, et al: Protease inhibitor combination therapies and perceptions of gay men regarding AIDS severity and the need to maintain safer sex.
The submission for tipranavir brings us one step closer to providing a potent treatment when the HI virus has developed resistance to most commercially available protease inhibitors.
Other considerations involve the amount of exposure a given patient is getting to the protease inhibitors and how adherent or motivated the patient is.
The rate ranged from 1% among those who took combination therapy without a protease inhibitor to 6% among those who took a single agent.
Thus far, we do not think that the full effect of protease inhibitors has kicked in'' in this country because of low use among many groups, particularly the poor, Gayle said.
The contents of this report is as follows: Chapter 1 Executive Summary Chapter 2 Introduction To The Proteases Chapter 3 Strategies For Protease Inhibitor Discovery Chapter 4 Protease Inhibitors In Infectious Disease Chapter 5 Protease Inhibitors In Inflammatory Disorders Chapter 6 Protease Inhibitors In Cancer Chapter 7 Protease Drugs In Other Conditions Chapter 8 Market Considerations and Forecasts Chapter 9 Company Profiles Chapter 10 Trends and Opportunities Chapter 11 Glossary
Tipranavir: This protease inhibitor is widely believed to be the next HIV med to be approved by the Food and Drug Administration (FDA).
Richard Haubrich of the University of California, San Diego and his colleagues gave various doses of TMC114 to almost 400 people for whom a different protease inhibitor was failing to control HIV.
The participants, all of whom had taken 1 prior protease inhibitor but were naive to NNRTIs, also took the NNRTI nevirapine (Viramune) plus 2 NRTIs.